ArticleThe New England journal of medicine2019
Dolutegravir Use at Conception - Additional Surveillance Data from Botswana.
Abstract readLetter
In one paragraph
Article in The New England journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- CombinedActa biochimica et biophysica Sinica · 2025Article
- Obstetric and newborn outcomes of mothers with and without HIV infection in Anaka general hospital in Northern Uganda.PloS one · 2025Article
- Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non-case study from the global pharmacovigilance database VigiBase®.Pharmacology research & perspectives · 2024Article
- Metabolic implications and safety of dolutegravir use in pregnancy.The lancet. HIV · 2023Review
- The End Is in Sight: Current Strategies for the Elimination of HIV Vertical Transmission.Current HIV/AIDS reports · 2023Review
- Antiretroviral Options and Treatment Decisions During Pregnancy.Paediatric drugs · 2023Review
- The burden, prevention and care of infants and children with congenital anomalies in sub-Saharan Africa: A scoping review.PLOS global public health · 2023Article
- Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors.Frontiers in toxicology · 2023Article
- HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment.Pharmaceuticals (Basel, Switzerland) · 2022Review
- A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.Retrovirology · 2022Review
- HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis.PLOS global public health · 2022Article
- Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study.Annals of internal medicine · 2022Observational
- Protocol for active safety monitoring of a cohort of patients using a dolutegravir-based antiretroviral regimen in Mozambique.BMJ open · 2021Article
- Limited surface examination to evaluate potential teratogens in a resource-limited setting.Birth defects research · 2021Article
- Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note.BMJ case reports · 2021Article
- Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.The lancet. HIV · 2021Article
- Weight gain during pregnancy among women initiating dolutegravir in Botswana.EClinicalMedicine · 2020Article
- Epilepsy management in pregnant HIV+ women in sub-Saharan Africa, clinical aspects to consider: a scoping review.BMC medicine · 2020Article
- Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis.EClinicalMedicine · 2020Article
- Safety of in-utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected.AIDS (London, England) · 2020Article
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Mmakgomo M RaesimaBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Chibuike M OgbuaboBotswana-University of Maryland School of Medicine Health Initiative, Gaborone, Botswana.
Vasavi ThomasCenters for Disease Control and Prevention, Gaborone, Botswana cqi6@cdc.gov.
Sara E ForhanCenters for Disease Control and Prevention, Atlanta, GA.
Gadzikanani GokatwengBotswana-University of Maryland School of Medicine Health Initiative, Gaborone, Botswana.
Eldah DintwaBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Chipo PetloBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Catherine Motswere-ChirwaCenters for Disease Control and Prevention, Gaborone, Botswana.
Elizabeth M RaboldCenters for Disease Control and Prevention, Atlanta, GA.
Sarah C TinkerCenters for Disease Control and Prevention, Atlanta, GA.
Shifawu OdunsiPeace Corps, Gaborone, Botswana.
Sifelani MalimaBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Omphemetse MmunyaneBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Thusoetsile ModiseBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Kelame KefitlhileBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Kunle DareCenters for Disease Control and Prevention, Gaborone, Botswana.
Mpho LetebeleCenters for Disease Control and Prevention, Gaborone, Botswana.
Michelle E RolandCenters for Disease Control and Prevention, Gaborone, Botswana.
Cynthia A MooreCenters for Disease Control and Prevention, Atlanta, GA.
Surbhi ModiCenters for Disease Control and Prevention, Atlanta, GA.ORCID 0000-0003-2143-672X
Dhelia M WilliamsonCenters for Disease Control and Prevention, Atlanta, GA.
Funding
CGH CDC HHS U2G GH001490U.S. President's Emergency Plan for AIDS Relief GH001490U.S. President's Emergency Plan for AIDS Relief GH002027
Abstract
PubMed holds no abstract for this paper.
Indexed as
BotswanaDolutegravirFemaleFetusHeterocyclic Compounds, 3-RingHIV InfectionsHIV Integrase InhibitorsHumansInfant, NewbornNeural Tube DefectsOxazinesPiperazinesPopulation SurveillancePregnancyPregnancy Complications, InfectiousPrevalenceDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.